First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: Results of the first in human BICARE trial

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 3, 2014, Pages 405-411

  Yu, Mengyue ^a   Xu, Bo ^a   Kandzari, David E ^b   Wu, Yongjian ^a   Yan, Hongbing ^a   Chen, Jue ^a   Qian, Jie ^a   Qiao, Shubin ^a   Yang, Yuejin ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

^b PIEDMONT HEART INSTITUTE   (United States)

Author keywords

drug eluting stent; first in human trial; polymer; probucol; sirolimus

Indexed keywords

DRUG-ELUTING STENT; FIRST IN HUMAN TRIAL; POLYMER; PROBUCOL; SIROLIMUS;

CARDIOVASCULAR AGENTS; CHINA; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG COMBINATIONS; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PROBUCOL; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84893780328     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25129     Document Type: Article

References (26)

1. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
2. Kimura T, Morimoto T, Nakagawa Y, et al.; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125: 584-591.
3. Byrne RA, Kastrati A, Tiroch K, et al.; ISAR-TEST-2 Investigators. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents. J Am Coll Cardiol 2010; 55: 2536-2543.
4. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
5. Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis. J Am Coll Cardiol Intv 2012; 5: 12-20.
6. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-1322.
7. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.
8. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
9. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
10. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
11. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
12. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R,. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57; 390-398.
13. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990; 82: 1193-1202.
14. Desch S, Schloma D, Möbius-Winkler S, et al. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. Cathet Cardiovasc Interv 2011; 4: 452-459.
15. Ruef J, Störger H, Schwarz F, Haase J,. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Cathet Cardiovasc Interv 2008; 71: 333-339.
16. Costa JR Jr, Abizaid A, Costa R, et al. One-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. J Am Coll Cardiol Interv 2009; 2: 422-427.
17. Massberg S, Byrne RA, Kastrati A, et al. Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators. Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011; 124: 624-632.
18. Wessely R, Schomig A, Kastrati A,. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006; 47: 708-714.
19. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
20. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011; 58: 1844-1854.
21. Tanous D, Brasen JH, Choy K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis 2006; 189: 342-349.
22. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-195.
23. Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005; 1: 157-164.
24. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1: 58-65.
25. Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 2007; 1: 50-53.
26. Moore P, Barlis P, Spiro J, et al. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. J Am Coll Cardiol Intv 2009; 2: 437-444.